HCR Wealth Advisors Grows Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

HCR Wealth Advisors boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 14.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,070 shares of the medical equipment provider’s stock after acquiring an additional 133 shares during the quarter. HCR Wealth Advisors’ holdings in Intuitive Surgical were worth $476,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after acquiring an additional 493,126 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock worth $5,726,102,000 after acquiring an additional 272,741 shares in the last quarter. Capital World Investors boosted its holdings in Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after purchasing an additional 73,634 shares during the period. Edgewood Management LLC increased its holdings in Intuitive Surgical by 7.9% during the 4th quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after purchasing an additional 374,667 shares during the period. Finally, Jennison Associates LLC raised its position in Intuitive Surgical by 4.6% in the 1st quarter. Jennison Associates LLC now owns 4,488,343 shares of the medical equipment provider’s stock valued at $1,791,253,000 after purchasing an additional 198,483 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $471.82 on Monday. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $493.97. The stock’s 50 day moving average price is $458.74 and its 200 day moving average price is $418.53. The company has a market cap of $167.66 billion, a PE ratio of 85.17, a price-to-earnings-growth ratio of 5.20 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The business’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.18 EPS. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares of the company’s stock, valued at $5,441,507.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $421.06, for a total transaction of $589,484.00. The disclosure for this sale can be found here. Insiders sold 51,417 shares of company stock worth $24,601,076 over the last three months. 0.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on ISRG shares. JPMorgan Chase & Co. increased their price objective on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a research report on Friday, July 19th. Barclays upped their price objective on shares of Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Evercore ISI cut their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating on the stock in a research report on Friday, July 19th. Robert W. Baird upped their target price on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research report on Friday, July 19th. Finally, BTIG Research lifted their price target on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $446.45.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.